ALA exclusive iNKT technology option with Baylor
MELBOURNE, AUSTRALIA 5 May 2025: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat cancer, is pleased to announce that it has entered into an exclusive Option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform (Option).
Arovella’s CEO and Managing Director, Dr Michael Baker, commented: “Arovella believes in the potential of CAR-iNKT cells, and the team is excited by the prospect of working with Baylor to examine the potential for combining our technologies to enhance the CAR-iNKT platform. The potential to access two new solid tumour targets is an excellent opportunity for Arovella to leverage the progress it has made in developing its proprietary manufacturing process.”